UnitedHealth’s stock just had its worst day in 9 years

Amy Baxter | | Health Exec | Policy & Regulations
Stocks

UnitedHealth Group saw its worst stock day in nearly 9 years on Feb. 24, with shares dropping 7.8%, according to MarketWatch.

While stocks around the world were dropping the same week due to coronavirus, or Covid-19, fears, investors of UnitedHealth were likely influenced by the Democratic primary results in Nevada at the same time. Sen. Bernie Sanders (I-Vt.), a staunch supporter of a single-payer healthcare system in the U.S., claimed victory among a field of Democratic candidates. Sanders’ policies, if elected, could represent a danger to private healthcare companies and those on Wall Street.

“The manner of his victory in Nevada may have spooked investors,” MarketWatch reported.

However, when Sanders won the New Hampshire Democratic primary in the previous weeks, stock of both Centene and UnitedHealth Group, which owns the nation’s largest health insurance company, rose. Investors at that time more likely believed Sanders would be unable to beat President Trump in the general election.

See the full story below:

UnitedHealth stock suffers worst day in nearly 9 years as Sanders’ Nevada win s…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”